Bank of Montreal Can Takes $3.95 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Bank of Montreal Can purchased a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 191,893 shares of the company’s stock, valued at approximately $3,949,000. Bank of Montreal Can owned 0.47% of Enliven Therapeutics as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in the company. FMR LLC purchased a new stake in shares of Enliven Therapeutics during the 1st quarter valued at approximately $69,280,000. Fairmount Funds Management LLC acquired a new stake in Enliven Therapeutics in the 1st quarter valued at approximately $42,156,000. Commodore Capital LP acquired a new stake in Enliven Therapeutics in the 1st quarter valued at approximately $37,917,000. Boxer Capital LLC acquired a new stake in Enliven Therapeutics in the 1st quarter valued at approximately $15,563,000. Finally, Logos Global Management LP acquired a new stake in Enliven Therapeutics in the 1st quarter valued at approximately $8,787,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

Enliven Therapeutics stock opened at $13.00 on Monday. Enliven Therapeutics, Inc. has a fifty-two week low of $10.89 and a fifty-two week high of $25.34. The firm has a 50 day moving average price of $14.02 and a 200 day moving average price of $17.36. The company has a market capitalization of $535.60 million, a PE ratio of 4.35 and a beta of 1.13.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Thursday, August 10th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.01). As a group, equities research analysts forecast that Enliven Therapeutics, Inc. will post -2.12 earnings per share for the current year.

Insiders Place Their Bets

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 12,000 shares of the business’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $13.62, for a total value of $163,440.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, major shareholder 5Am Partners Vi, Llc sold 440,000 shares of the business’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $16.00, for a total transaction of $7,040,000.00. Following the completion of the transaction, the insider now owns 887,507 shares in the company, valued at $14,200,112. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Joseph P. Lyssikatos sold 12,000 shares of the business’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $13.62, for a total transaction of $163,440.00. The disclosure for this sale can be found here. Insiders sold a total of 661,500 shares of company stock worth $10,331,660 over the last 90 days. Corporate insiders own 45.80% of the company’s stock.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene.